Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.Peer-Reviewed Original ResearchBaseline PSA levelsPET/CTLow PSA levelsPSA levelsTreatment recommendationsDisease managementLow baseline PSA levelsBiochemically recurrent prostate cancerPositive PET/CTBaseline PSA valuePhase 3 studySubset of patientsRecurrent prostate cancerProstate cancer patientsAvailable clinical informationConventional imaging resultsYears of ageDisease management plansManagement QuestionnaireEquivocal imagingEvaluable patientsNegative PETSystemic therapyDisease recurrenceInitial staging